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Abstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-cholesterol and 
improve endothelial function. In addition to lipid-lowering, statins may exert pleiotropic 
(nonlipid lowering) effects on microvascular function. We compared the neurophysiological and 
vascular responses of dietary control and treatment with 10 mg of rosuvastatin in 16 subjects 
with neuropathy and established type 2 diabetes. Skin blood flow (SkBF) measurements were 
measured at baseline, after 18 weeks of diet, and after 18 weeks of diet and treatment with 
rosuvastatin in response to local warming and ischemia reperfusion. The study results show that 
total cholesterol (196.50 ± 8.02 to 134.88 ± 10.86 mg/dL) and LDL-cholesterol (114 ± 10.4 
to 63.4 ± 8.48 mg/dL) decreased significantly after 18 weeks of rosuvastatin, but not after 
18 weeks of diet. Neuropathy scores decreased from 8.34 ± 1.26 at baseline to 6.00 ± 0.90 
after rosuvastatin treatment. Basal SkBF was significantly different from baseline, 6.81 ± 0.42 
to 9.92 ± 0.78 after rosuvastatin treatment (P  0.001). These results indicate that rosuvastatin 
therapy positively changed basal SkBF and measures of neurovascular function. Although 
there was a profound lipid lowering, it is not clear that this mediated the increases in SkBF 
and decreases in neuropathy scores.
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Introduction
Metabolic abnormalities in diabetes are associated with microvascular dysfunction. 
We have documented the existence of defective blood flow in the skin of people with 
type 2 diabetes that cosegregates with dyslipidemia, hypertension, insulin resistance, 
and markers of inflammation.1,2 Impaired blood flow, which often precedes the devel-
opment of diabetes, is a major contributor to nerve dysfunction and skin integrity 
which leads to foot ulcers and amputation. Improving the microvascular perfusion of 
peripheral nerves is of particular importance since diabetic neuropathy is the main 
contributor to lower extremity amputations in the US.3
Rosuvastatin, which has been widely used to treat hypercholesterolemia, selectively 
competes to inhibit HMG-CoA reductase. Clinical trial data have reported that patients 
achieve significant reductions in low-density lipoprotein (LDL)-cholesterol after being 
treated with 10 mg rosuvastatin for 6 weeks.4 Patients treated with rosuvastatin have 
been shown to not only attain their cholesterol goals compared to patients taking 
other statins,5 but also achieve significant improvement in endothelial function.6 This 
is especially important since elevated plasma lipids and oxidative stress markers are 
risk factors for neuropathy.7 Rosuvastatin has also been shown to significantly reduce 
the progression of maximum carotid intima-media thickness.8 In the ASTEROID trial, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 20
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Nissen and colleagues reported a significant regression of 
coronary atherosclerosis in patients when placed on high-
intensity rosuvastatin therapy.9
The benefits of statin therapy for lipid control are well 
known, but there is less known about how this class of 
drugs affects microvascular function and how this relates 
to lipid lowering. Statins have been shown to have nonlipid 
effects on microvascular perfusion. Most recently, a study 
by Medina et al evaluated the pleiotropic effects of simvas-
tatin on retinal microvascular endothelium and determined 
that simvastatin offered the beneficial effect of reducing 
ischemia.10 Another study by Fichtlscherer et al showed 
the positive effects of statins, not ezetimibe, on endothe-
lial function in patients with coronary artery disease.11 
In addition, there are some reports that show statins actu-
ally improve neurovascular function.12 This improvement 
has been described to be independent of the changes in 
serum cholesterol which involve nonlipid mechanisms that 
decrease smooth muscle cell migration and proliferation, as 
well as decrease the in vitro accumulation of macrophages.13 
Statins have not only been shown to decrease the inflam-
matory response by decreasing the production of pro-
inflammatory cytokines such as C-reactive protein and 
interleukin 6, but also improve vasomotor function.14 The 
addition of mevolonate, the HMG CoA reductase precursor, 
significantly reduced the improvement in vascular function, 
implying that the vascular benefits are not related to lipid 
concentrations.15 Using an animal model of diabetes, Cam-
eron and colleagues have demonstrated that rosuvastatin 
corrects the sciatic motor and saphenous sensory (large 
fiber) nerve conduction defect and sciatic endoneurial blood 
flow, thus improving microvascular function.16
The objective of this study was to determine the efficacy 
of 18 weeks of 10 mg/day oral rosuvastatin therapy super-
imposed on an American Diabetes Association (ADA) diet 
on endothelial-dependent and heat-induced vasodilation in 
subjects with type 2 diabetes and neuropathy.
Methods
Patient population
This study was a within-subject repeated measures design that 
compared the neurovascular responses of 16 subjects with 
type 2 diabetes and neuropathy at baseline, after 18 weeks 
of an ADA diet and then 18 weeks of diet and rosuvastatin. 
Initially, 22 subjects were enrolled, but 4 chose to discontinue 
participation, one whom experienced dizziness and another 
experienced burning in the upper extremities. Two other 
subjects were excluded because they exhibited a number 
of baseline clinical measures outside the range defined for 
inclusion. Inclusion criteria included LDL-cholesterol levels 
above 100 mg/dL and a minimum of 3 years after diagnosis 
of type 2 diabetes.
Subjects with microalbuminuria, recent myocardial 
infarction or cerebrovascular incident, such as stroke within 
the previous 6 months were excluded from the study because 
macrovascular disease could affect the microcirculatory 
responsiveness of the neurovascular measurements and 
such subjects were likely to be taking statins. Subjects 
using statins as well as bile acid sequestrants, fibric acid 
derivatives, and antacids were also excluded. Subjects were 
allowed the stable use (3 months or more) of angiotensin-
converting enzyme (ACE) inhibitors, angiotensin-receptor 
blockers (ARBs), and other hypertensive agents, and dosage 
schedule was not changed during the course of the study. 
Subjects’ were maintained on their diabetes-treatment 
regimen which consisted of a combination of oral agents 
(metformin, thiazolidinediones, and sulfonylureas), insulin, 
and diet. The study protocol was reviewed and approved by 
the Institutional Review Board of Eastern Virginia Medical 
School and all subjects gave voluntary informed written 
consent before participation.
Assessment of neurovascular function
Neurophysiological responses were measured at baseline, 
after 18 weeks of dietary control, and after 18 weeks of 
treatment with 10 mg of rosuvastatin. This time course was 
chosen because previously, we have demonstrated that it is 
feasible to pharmacologically alter subjective and objec-
tive measures of neurovascular function in 18 weeks.1,17,18 
The primary efficacy measures were skin perfusion. Vas-
cular responses were measured non-invasively using laser 
Doppler techniques.19 Laser Doppler flow (LDF) measure-
ments are a reliable index of SkBF and are uninfluenced 
by blood flow in the underlying muscle.20 The Periflux 
Master Unit PF4001-2 and the Peritemp heating module 
with sensor PF4005-3 (Perimed, Inc., Smithtown, NY, 
USA) were used. Skin blood flow (SkBF) was measured 
at the brachial artery, medial to the bicipital tendon and 
over the fingertip in response to five minutes of upper arm 
occlusion. SkBF was measured on the dorsum of the foot 
and the plantar surface of the great toe in response to heat. 
Heat was applied for 10 minutes at 32 °C, 10 minutes at 
40 °C, and 20 minutes at 44 °C to give a total testing time 
of 40 minutes. Secondary measures also included nerve 
conduction testing, complete physical, and neurologic 
examinations.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 21
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Nerve conduction testing was used to measure the nerve 
conduction velocity (NCV) and amplitudes of specific nerves 
using the NeuroMax (Xltek Inc., Ontario, Canada). The left 
peroneal, sural nerves, and left ulnar sensory responses were 
evaluated for each subject. This battery of electrophysiological 
tests was used to determine differences in neural activity as well 
as eliminate other causes of neuropathy. All subjects received 
a complete pre and post treatment neurological examination. 
This exam is comprised of six components including the 
neurological symptom score, cranial nerve function, and an 
evaluation of muscle weakness, muscle wasting, reflexes and 
sensory function of upper and lower limbs bilaterally. The six 
components of the neurological exam were added to gener-
ate a total neuropathy score, which was analyzed for changes 
before and after rosuvastatin therapy. A subanalysis was also 
performed on the motor and sensory components of the exam. 
The neurological exam contains all components of the nerve 
impairment score – lower limb (NIS-LL), originally developed 
by Dyck and colleagues.21 Therefore, we were also able to 
do an analysis of the total NIS-LL and each of its elements. 
Secondary measures included fasting blood tests for meta-
bolic parameters (insulin, C-peptide, glucose, hemoglobin A1c 
[HbA1c]) as well as safety measures to monitor liver enzymes 
(within three times the upper limit of normal) and kidney func-
tion (creatinine within normal limits). Quantitative sensory 
tests (QST) were used to evaluate peripheral sensory percep-
tion. These tests measure vibratory, proprioceptive, tactile, 
pain, and thermal nerve function. Autonomic function tests 
were used to evaluate autonomic neuropathy and are based on 
detection of heart rate and blood pressure response to a series 
of breathing maneuvers.
ADA diet
All subjects were instructed to follow a specified nutritional 
diet established by the ADA.22 The nutritional guidelines 
recommended by the ADA include eating carbohydrates from 
fruits, vegetables, whole grains, legumes and low-fat milk. 
They also include eating fiber-rich foods and nonfried fish, 
as well as limiting saturated fats (7% total caloric intake), 
trans fats, and cholesterol (200 mg/day). A certified dieti-
tian provided dietary support approximately every 6 weeks. 
All subjects continued to follow dietary guidelines during 
rosuvastatin therapy.
Statistical analysis
To analyze the results, paired t-tests were used to assess 
within-subjects change between the three study phases across 
all study variables. Matched pairs with missing data points 
were discarded therefore some variables have an N  16. 
Associations between clinical values and various measures 
of neuropathy and associated variables were examined with 
Pearson correlations. P values less than or equal to 0.05 were 
regarded as significant. All data analyses were conducted 
using SPSS version 15 software.
Results
Sixteen subjects were included in this study (10 females and 
6 males): 11 Caucasian, 4 African American, and 1 Hispanic. 
Average age of the subjects was 56.08 ± 2.15 years, with 
8.42 ± 0.89 years average length of diabetes. Laboratory 
parameters are listed in Table 1.
There were no significant differences in the lipid pro-
file after ADA diet alone. After the addition of rosuvas-
Table 1 Summary of demographic and laboratory results
Demographic and Lab 
characteristics
Normal values Pre-treatment ADA diet ADA diet and 
rosuvastatin
Body mass index 19–25 kg/m2 36.61 ± 2.37 36.88 ± 2.2 36.25 ± 2.12
Systolic blood pressure 120 mmhg 142.44 ± 5.01 132.94 ± 5.07 130.0 ± 4.84
Diastolic blood pressure 80 mmhg 79.94 ± 2.36 74.5 ± 2.53 74.75 ± 2.66
Fasting plasma glucose 
(mg/dL)
70–110 mg/dL 157.94 ± 16.22 153.67 ± 21.62 176.19 ± 19.48
c Peptide (ng/mL) 0.9–4 ng/mL 3.02 ± 0.56 3.48 ± 0.48 3.81 ± 0.61*
hbA1c (%) 4.3%–6.1% 8.09 ± 0.47 7.84 ± 0.56# 8.96 ± 0.62*
insulin (uiU/mL) 5–15 uiU/mL 13.40 ± 2.84 12.62 ± 3.09 10.48 ± 3.21
Triglycerides (mg/dL) 10–150 mg/dL 128.81 ± 14.58 128.58 ± 19.76 127.25 ± 20.74
Total cholesterol (mg/dL) 0–200 mg/dL 196.50 ± 8.02 193.42 ± 11.40# 134.88 ± 10.86*
hDL-c (mg/dL) 35–95 mg/dL 49.41 ± 5.40 51.0 ± 4.94 49.25 ± 4.47
LDL-c (mg/dL) 50–160 mg/dL 113.7 ± 13.1 113.63 ± 9.77# 60.19 ± 8.56*
Values are mean ± Se, p  0.05. #Results are significant from ADA diet combined with rosuvastatin. *Results are significant from pre-treatment to ADA diet combined with 
rosuvastatin.
Abbreviations: hbA1c, hemoglobin A1c; hDL-c, high density lipoprotein; LDL-c, low density lipoprotein.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 22
Parson et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
tatin, however, significant differences in lipid levels were 
shown with LDL cholesterol improving by 47% and total 
cholesterol improving by 31%. Other significant values 
included an increase in C-peptide and HbA1c. The ADA 
diet for 18 weeks produced no significant differences in 
any laboratory parameter from pretreatment (baseline) to 
ADA diet (Table 1).
Mean baseline median skin blood flow of the foot dor-
sum (n = 16), a primary endpoint, increased significantly 
from study start to the end of rosuvastatin therapy phase 
(delta = 2.76 ± 0.68, P = 0.001) (Figure 1). Similar trends were 
observed on the foot dorsum at 40 °C median (delta 3.4 ± 1.52, 
P = 0.04) and 44 °C peak (delta = 36.2 ± 13.1, P = 0.015). 
No significant differences in skin blood flow measured over 
the toe after occlusion were observed.
Treatment with rosuvastatin improved the total neu-
ropathy score (Table 2). Bilateral reductions in total 
neuropathy scores were observed from study start to the 
end of rosuvastatin treatment phase (delta = −2.33 ± 1.1, 
P = 0.05). The NIS-LL was initially analyzed for all 
16 patients. Another analysis was performed after the 
removal of one outlier (defined as three standard deviations 
from the mean). This patient had a significant change in 
health status that resulted in a large change in her physical 
0
0
10
20
30
40
50
60
70
Time  (min)
P
e
r
f
u
s
i
o
n
 
u
n
i
t
s
ADA diet alone
ADA diet & rosuvastatin
44 °C
10 20 30 40
32 °C 40 °C
P = 0.001
A
0
2
4
6
8
10
12
Pre treatment ADA diet & rosuvastatin
P
e
r
f
u
s
i
o
n
 
u
n
i
t
s
Baseline mean *
B
Figure 1 Skin blood flow graphs. A) Skin perfusion of the foot dorsum (during heating) at baseline (American Diabetes Diet [ADA] diet alone) and after 18 weeks of ADA 
diet and rosuvastatin (n = 16). B) A bar graph representation of the significant differences in baseline blood flow.
*Results are significant from pre-treatment to ADA diet combined with rosuvastatin, P = 0.001.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 23
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condition unrelated to rosuvastatin therapy. This change 
was not reflected in other neurovascular measures. There 
was a significant improvement in the reflex component of 
the NIS-LL (P = 0.02), sensation component of the NIS-
LL (0.004), and the NIS-LL total (P = 0.007). QST and 
autonomic function tests did not significantly improve 
after ADA diet or treatment with rosuvastatin (Table 3). 
There were also no significant differences in nerve con-
duction measurements (Table 3). These results indicate 
that 18 weeks of rosuvastatin therapy improves certain 
aspects of neurovascular function and did not cause adverse 
changes in quantitative electrophysiological measurements 
of nerve function. Correlations were sought between the 
effects of rosuvastatin on LDL-cholesterol and measures 
of neurovascular function, but none were found.
Discussion
The cardinal findings in this study were that 18 weeks of 
rosuvastatin significantly improved the lipid profile of all 
subjects, while improving basal skin blood flow and the 
total neuropathy score assessed during clinical neurological 
examination. In our study 18 weeks of rosuvastatin therapy 
lowered LDL-cholesterol and total cholesterol by 47% and 
31%, respectively. Regression analysis of the improvements in 
total and LDL-cholesterol did not, however, support a direct 
correlation with the improvement in neurovascular function 
Table 3 effects of American Diabetes Association (ADA) diet and ADA diet + rosuvastatin on somatic and autonomic nerve function
Nerve function measures Pre-treatment (n =16) ADA diet (n = 16) ADA diet + rosuvastatin (n = 16)
Sural amplitude 8.43 ± 1.60* 7.33 ± 1.25 8.68 ± 1.48
Sural cV 39.12 ± 2.75 36.90 ± 3.78 36.06 ± 3.59
Peroneal amplitude 4.06 ± 0.68 4.08 ± 0.68 3.97 ± 0.68
Peroneal cV 41.69 ± 1.20 42.35 ± 1.21 41.96 ± 1.58
Vibration 16.59 ± 2.77 18.81 ± 4.37 19.93 ± 4.10
Pressure 3.53 ± 0.22 3.47 ± 0.18 3.64 ± 0.22
cold sensation 6.41 ± 0.91 6.16 ± 0.95 6.16 ± 0.93
Warm sensation 7.96 ± 1.07 6.96 ± 1.03 7.61 ± 1.04
cold pain 17.56 ± 3.86 18.78 ± 3.61 19.68 ± 3.11
heat pain 15.17 ± 0.95 14.67 ± 1.15 13.15 ± 0.93
e/i ratio 1.26 ± 0.14 1.14 ± 0.03 1.20 ± 0.08
Valsalva ratio 1.25 ± 0.05 1.23 ± 0.06 1.57 ± 0.31
30/15 ratio 3.81 ± 1.29 3.97 ± 0.93 2.86 ± 0.57
Abbreviations: cV, conduction velocity; autonomic function measures of heart rate variability during: e/i ratio, expiration/inspiration ratio;   Valsalva ratio, Valsalva maneuver 
(forcible exhalation against a closed airway); 30/15 ratio, electrocardiogram R-R interval to upright posture.
Table 2 neurological symptom and impairment scores
Neurologic Impairment 
measures
Pre-treatment ADA diet and 
rosuvastatin
P value
neurologic symptom score 3.09 ± 0.72 2.03 ± 0.42 0.09
Sensory score 3.56 ± 0.60 2.56 ± 0.49 0.13
Motor score 1.69 ± 0.30 1.41 ± 0.25 0.31
Total neuropathy score 8.34 ± 1.26 6.00 ± 0.90 0.05*
NIS-LL (N = 15)
NIS-LL Reflexes (n = 15) 1.87 ± 0.14 1.37 ± 0.23 0.022
niS-LL Muscle weakness (n = 15) 0.73 ± 0.37 1.27 ± 0.40 0.20
niS-LL Sensation (n = 15) 6.40 ± 0.76 3.27 ± 0.86 0.004
niS-LL Total score (n = 15) 9.00 ± 1.00 5.9 ± 0.94 0.007
Values are mean ± Se, p  0.05. *Results are significant from pre-treatment to ADA diet combined with rosuvastatin. *During the analysis of the NIS-LL and its components, 
one person was a clear outlier and was excluded from the analysis.
Abbreviation: niS-LL, nerve impairment score-lower limb.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 24
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and neuropathy symptoms. Our results indicate significant 
improvements in microvascular perfusion despite actual 
deterioration in glucose or HbA1c levels and an increase in 
C-peptide. This finding has been previously reported23,24 and 
was clinically insignificant in this study. Diabetes control 
should be carefully monitored when patients receive rosuv-
astatin therapy. Rosuvastatin did improve neuropathy scores 
(P = 0.007), but we found no significant changes in objec-
tive measures, which include nerve conduction, autonomic 
neuropathy testing, or QST results. It is also important to 
mention that several studies have reported an improvement 
in nerve function with stringent diet control alone.25,26 In 
the study reported here, there was a trend towards improved 
microvascular function in many parameters on diet alone; 
however, none of these were significant without the addition 
of rosuvastatin therapy.
In previous studies, we have shown that there is a pro-
found defect in SkBF in individuals with type 2 diabetes 
that directly correlates with nerve dysfunction, indices 
of insulin resistance, triglyceride levels and markers of 
inflammation.1,2,27 The significant improvement in skin 
perfusion observed with rosuvastatin therapy may be 
linked to the balance between nitric oxide synthesis and 
endothelin regulation.28 Rosuvastatin may alter the balance 
in favor of vasodilation by increasing endothelial-derived 
nitric oxide (NO) and downregulating endothelin 1, a 
vasoconstrictor. A short-term study on lipid-lowering 
therapy with statins in humans showed improvements in 
endothelial function and nitric oxide availability. In 41 
hypercholesterolemic subjects, a significant decrease in 
LDL-cholesterol improved endothelium-dependent vaso-
dilation and decreased oxidative stress.15 The decrease in 
lipid levels during rosuvastatin therapy with the subsequent 
improvement in vascular function might imply that lipotox-
icity and increases in oxidative stress cause microvascular 
dysfunction, although this theory remains controversial. 
In our study, however, there was no direct correlation 
between the indices of improved neurovascular function 
and the changes in lipoprotein metabolism.
In previous studies, we have shown that the insulin sen-
sitizers, rosiglitazone27 and pioglitazone29 improve blood 
flow marginally, but have diametrically opposite effects on 
nitrosative stress. Rosiglitazone increases NO while improv-
ing blood flow,27 whereas pioglitazone reduced nitrosative 
stress29 while increasing blood flow and had profound effects 
on lipids.30,31 Similarly, in this study, we show improvement 
in nerve function and blood flow which were independent of 
the changes in total and LDL-cholesterol. It is quite plausible 
that there may be effects of statins on microvascular function 
outside of their lipid-lowering properties.
In a recent report from Freemantle, Australia, Davis and 
colleagues conducted a biphasic study, which concluded 
that statin and fibric acid derivatives reduced the overall risk 
for developing neuropathy. The cross-sectional phase of the 
study evaluated 1294 patients with type 2 diabetes (average 
age of 63.8 and 4 years of diabetes duration) of which 31% 
of patients had peripheral neuropathy at baseline. Approxi-
mately 7% of these patients were on statin therapy and 4% 
were on fibrate therapy. After the independent predictors of 
age, height, duration of diabetes, systolic blood pressure, 
abdominal girth, and obesity were considered, the study 
concluded that fibric acid therapy reduced the likelihood of 
neuropathy (P  0.001). In the longitudinal phase with a 
5-year follow up, 531 patients with type 2 diabetes (26% had 
peripheral sensory neuropathy at baseline and 74% were free 
of neuropathy) were examined. The best predictors of free-
dom from development of neuropathy were time dependent 
statin (P = 0.019) and fibrate use (P = 0.042).32
Similar findings were reported in the Steno Memorial 
study by Gaede and colleagues in which multifactorial 
therapy controlling blood pressure, HbA1c, and lipids using 
statins reduced the likelihood of development of autonomic 
neuropathy by 66%.33 While the Field study failed to dem-
onstrate a reduction in macrovascualr disease using fibrates, 
it did show a reduction of microvascular disease even when 
controlling for statin use.34
There are numerous animal studies that further sup-
port the beneficial effects of rosuvastatin on microvascular 
function. Nangle et al examined the effects of rosuvastatin 
on corpus cavernosum and aorta from streptozotocin-induced 
diabetic mice. These animals were treated with mevalon-
ate to assess the dependence of rosuvastatin’s effects on 
HMG-CoA reductase blockade. The diabetes induced reduc-
tion in NO mediated endothelium-dependent relaxation 
of the cavernosum and aorta were completely reversed by 
rosuvastatin. Co-treatment with mevalonate inhibited this 
beneficial action and total plasma cholesterol was unal-
tered by diabetes or treatment, supporting the theory of 
improved vascular function with statins through non-lipid 
related mechanisms.35 A second study, reported that rosuv-
astatin corrected the sciatic motor and saphenous sensory 
(large fiber) nerve conduction defect, sciatic endoneurial 
blood flow, thermal hyperalgesia (small fiber) and deficits 
in superior cervical ganglion. It also improved nitrergic and 
endothelium-derived hyperpolarizing factor-mediated blood 
flow in corpora cavernosa in diabetic mice.16 Yet another Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 25
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animal study reported that rosuvastatin exerts important 
anti-inflammatory effects in rats via inhibition of endothelial 
cell adhesion molecule expression and that this protective 
action is facilitated through the release of NO by the vascular 
endothelium.36
There have been several recent studies which described 
the pleiotropic (nonlipid lowering) effects of statins on 
microvascular function. In particular, a study conducted 
by Fichtlscherer et al compared venous plethysmography 
forearm blood flow responses to acetylcholine and sodium 
nitroprusside in four groups, de novo ezetimibe monotherapy, 
ezetimibe as an add on to chronic simvastatin therapy, dose 
escalation of simvastatin therapy, and de novo simvastatin 
therapy.11 After 4 weeks of lipid-lowering therapy, groups 
who received ezetimibe monotherapy and ezetimibe as an 
add-on therapy to simvastatin showed no increase in blood 
flow responses although LDL-cholesterol levels were sig-
nificantly reduced. In contrast, 4 weeks of monotherapy with 
atorvastatin showed lipid changes and significant increases 
in acetylcholine mediated blood flow. This study illustrated 
that despite the lipid lowering effects of both agents, only 
statin therapy displayed a pleiotropic effect of improved 
vascular function. In addition, Medina et al reports that 
a low dose simvastatin therapy has a beneficial affect on 
ischemic retinopathy.10 Low concentrations of simvastatin 
(0.1 µM) enhanced microvascular repair, significantly 
increased proliferation, and promoted migration, sprouting, 
and tubulogenesis in retinal microvascular endothelial cells. 
These results show that statins may reduce ischemia and 
promote angiogenic repair, thus preventing neovasculariza-
tion. High-dose simvastatin therapy appeared to hinder this 
reparative process.
Our study shows that rosuvastatin therapy appears 
to play a role in the microvascular defect in the skin and 
also improves other measures of neurovascular function, 
which appears to be irrespective of the changes in LDL-
cholesterol. Since our study investigated only rosuvastatin, 
we cannot conclude that this is a class effect for all statins. 
In addition, there may be additional beneficial results of 
rosuvastatin on vascular function that were not seen due 
to sample size. Further investigation is needed to evaluate 
the mechanistic aspects of rosuvastatin and to document 
whether the effects on nerve function hold true in long 
term statin therapy. Studies are needed using agents that 
affect the individual components of disturbed lipoprotein 
metabolism as well as other components of the metabolic 
syndrome that are conducive to the development of micro-
vascular dysfunction.37
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